Multiple once-daily subcutaneous doses of pasireotide were well tolerated in healthy male volunteers: a randomized, double-blind, placebo-controlled, cross-over, Phase I study
Christoph Beglinger(Kantonsspital Baselland), Pharis Mohideen(University of California San Diego), Emmanuel Bouillaud(Novartis (Switzerland)), Christelle Darstein(Novartis (Switzerland)), Ke Hu(Chinese Academy of Medical Sciences & Peking Union Medical College), Ying Wang(Shanghai University of Traditional Chinese Medicine), Yanfeng Wang(Wuhan University)
Cited by 18
Related Papers
Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease
|European Heart Journal|2006|537
Cytochrome P450 3A Inhibition by Ketoconazole Affects Prasugrel and Clopidogrel Pharmacokinetics and Pharmacodynamics Differently
|Clinical Pharmacology & Therapeutics|2007|323
Relevance of p‐glycoprotein for the enteral absorption of cyclosporin A: <i>in vitro‐in vivo</i> correlation
|British Journal of Pharmacology|1996|224
HIV protease inhibitor ritonavir: a more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833
|Biochemical Pharmacology|1999|186